Article
Pharmacogenomics of the cystic fibrosis transmembrane conductance regulator (CFTR) and the cystic fibrosis drug CPX using genome microarray analysis.
Molecular medicine (Cambridge, Mass.) - 1 Nov 1999
Srivastava M, Eidelman O, Pollard H B
Abstract excerpt
BACKGROUND: Cystic fibrosis (CF) is the most common lethal recessive disease affecting children in the U.S. and Europe. For this reason, a number of ongoing attempts are being made to treat the disease either by gene therapy or pharmacotherapy. Several phase 1 gene therapy trials have been completed, and a phase 2 clinical trial with the xanthine drug CPX is in progress. The protein coded by the principal CFTR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.